IDEAYA Biosciences Shows Strong Results for IDE849 in SCLC Trials
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) and Hengrui Pharma have unveiled impressive Phase 1 clinical trial data concerning IDE849 (SHR-4849), a promising candidate for treating small cell lung cancer (SCLC). At a recent oncology conference, the results highlighted a robust overall response rate (ORR) across diverse treatment cohorts.
Key Efficacy Findings
The study revealed a compelling ORR of 80.0% in patients receiving the 2.4 mg/kg dosage for second-line SCLC treatment. The findings suggest that IDE849 holds significant potential, with a confirmed ORR of 70.0% in this subset of patients. Furthermore, the study demonstrated a 73.7% ORR among all SCLC patients at the same dosage.
Noteworthy Observations in Advanced Cases
In cases involving patients with brain metastases, a confirmed ORR of 83.3% was achieved at the 2.4 mg/kg dose. Across various dosing levels, the data indicated that IDE849 could consistently demonstrate effectiveness, especially in patients who had already undergone multiple lines of prior therapy.
Median Progression-Free Survival Rates
The clinical trial also tracked the median progression-free survival (PFS), reporting an encouraging 6.7 months across all lines of treatment at doses ?2.4 mg/kg. Notably, the median PFS had not yet been reached in the second-line treatment cohort.
Safety Profile of IDE849
The safety profile of IDE849 appeared manageable, even across various dosing regimens. From a total of 100 patients treated, 48% experienced grade 3 or higher treatment-related adverse events, with neutropenia being the most frequently recorded issue. Importantly, the treatment-related discontinuation rate remained low at 2% with no treatment-related fatalities observed.
Implications for Future Development
The data showcased at the conference signals IDEAYA's commitment to advancing IDE849’s development not only in SCLC but also in neuroendocrine tumors (NETs) and other solid tumors with heightened DLL3 expression. This expansive vision anticipates meeting significant unmet needs in cancer therapy.
Company Overview
IDEAYA Biosciences stands at the forefront of precision medicine in oncology. Focused on uncovering transformative cancer therapies, the company integrates advanced methodologies in drug discovery and bioinformatics. With a deep pipeline catering to various cancer types, IDEAYA aims to create targeted treatments aligned with genetic disease drivers.
Frequently Asked Questions
What is IDE849?
IDE849 (SHR-4849) is a novel antibody-drug conjugate targeting DLL3 and designed to treat small cell lung cancer.
What were the response rates observed in the trial?
The trial showed an 80.0% ORR at the 2.4 mg/kg dose for patients in the second-line treatment setting.
What were the safety findings of the study?
The study found a manageable safety profile with 48% of patients experiencing grade 3 or higher treatment-related adverse events.
How long was the median progression-free survival?
The median PFS reported was 6.7 months across all lines of treatment at doses of IDE849 ?2.4 mg/kg.
What is IDEAYA's mission?
IDEAYA's mission is to pioneer precision oncology therapies that improve outcomes for cancer patients through targeted treatments aligned with the genetic drivers of disease.
